drugset / Trial / NCT02849990
A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy
Phase 2
Completed
22 enrolled
University of Washington
Janssen Scientific Affairs, LLC · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well apalutamide, abiraterone acetate, prednisone, degarelix, and indomethacin work in treating patients with prostate cancer that has spread from where it started to nearby tissue or lymph nodes before surgery. Androgen can cause the growth of tumor cells. Hormone therapy using apalutamide, abiraterone acetate, prednisone, degarelix, and indomethacin may fight prostate cancer by lowering the amount of androgen the body makes and/or blocking the use of androgen by the tumor cells.
Timeline
- Start
- 2017-03-09
- Primary completion
- 2018-12-10
- Completion
- 2020-12-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | — | Oral |
| Subject | Apalutamide | Small molecule | — | Oral |
| Subject | Degarelix | Other / unclassified | — | Subcutaneous |
| Subject | Indomethacin | Small molecule | — | Oral |
| Subject | Prednisone | Other / unclassified | — | Oral |